Back to Trades
Total Value
$NaN
Filing Date
Mar 27, 2026
1 transactions
Trade Summary
On Mar 18, 2026, Silberman David, Director, reported $NaN of Nasus Pharma Ltd (NSRX) across 1 transactions. The filing covers company securities and reflects balanced net activity of $NaN. Insider transactions are sourced from SEC Form 4 disclosures and should be reviewed alongside company fundamentals and the insider's broader trading history.
Company Information
- Company Name
- Nasus Pharma Ltd
- Ticker Symbol
- NSRX
- CIK
- 0002029039
Insider Information
- Name
- Silberman David
- Role
- Director
Filing Details
- Filing Date
- Mar 27, 2026
- Transaction Date
- Mar 18, 2026
- Accession Number
- 0001493152-26-013388
- Form Type
- 3
Want live alerts when Silberman David trades again?
Download Insider Trades to track NSRX, follow insiders, and get mobile alerts when new SEC Form 4 filings are published.
Footnotes
- (F1)Options to purchase 10,000 ordinary shares of the Issuer, no par value ("Ordinary Shares") were granted on December 11, 2025, with 2.0833% of the total grant vesting monthly following December 11, 2025. As of March 18, 2026, 10,000 options remain outstanding, of which 625 are vested and exercisable, at an exercise price of $5.38 per share, expiring December 11, 2035.